Molecular Pathology of the Genitourinary Tract: Prostate and Bladder.

[1]  M. Turner,et al.  Role of Hormonal and Other Factors in Human Prostate Cancer , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[2]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[3]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[4]  Kevin M. Bradley,et al.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer , 2008, Nature Genetics.

[5]  Pär Stattin,et al.  Cumulative association of five genetic variants with prostate cancer. , 2008, The New England journal of medicine.

[6]  K. Jennbacken,et al.  Altered expression of genes regulating angiogenesis in experimental androgen‐independent prostate cancer , 2008, The Prostate.

[7]  T. Ganz,et al.  Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. , 2008, Molecular immunology.

[8]  I. Thompson,et al.  Association of polymorphisms in TGFB1 and prostate cancer prognosis. , 2008, The Journal of urology.

[9]  Yao-Tseng Chen,et al.  Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma. , 2008, Archives of pathology & laboratory medicine.

[10]  Ganesh Venkatraman,et al.  Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. , 2008, Cancer letters.

[11]  R. Eeles,et al.  Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype , 2008, British Journal of Cancer.

[12]  Mitsutoshi Nakamura,et al.  Prostate cancer antigen‐1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer , 2007, Cancer science.

[13]  Mitsutoshi Nakamura,et al.  HRK inactivation associated with promoter methylation and LOH in prostate cancer , 2008, The Prostate.

[14]  M. Fernö,et al.  Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? , 2008, Urologic oncology.

[15]  E. Zwarthoff,et al.  Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. , 2008, Neoplasia.

[16]  I. Kovalszky,et al.  Detection of bladder cancer from the urine using fluorescencein situ hybridization technique , 2008, Pathology & Oncology Research.

[17]  J. Tímár,et al.  Genomics of prostate cancer: Is there anything to „translate”? , 2008, Pathology & Oncology Research.

[18]  J. Carpten,et al.  Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. , 2007, Journal of the National Cancer Institute.

[19]  W. Min,et al.  Genetic and biologic evidence that implicates a gene in aggressive prostate cancer. , 2007, Journal of the National Cancer Institute.

[20]  Jaime Rodriguez-Canales,et al.  Global Expression Analysis of Prostate Cancer-associated Stroma and Epithelia , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[21]  G. Nesi,et al.  Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. , 2007, The Journal of surgical research.

[22]  A. Gudkov,et al.  Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity , 2007, The Prostate.

[23]  N. Socci,et al.  Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. , 2007, The American journal of pathology.

[24]  Y. Lotan,et al.  Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. , 2007, Human pathology.

[25]  S. Lenk,et al.  TP53 mutation in prostate needle biopsies--comparison with patients follow-up. , 2007, Anticancer research.

[26]  A. S. Salinas-Sánchez,et al.  Sensitivity and Specificity of P53 Protein Detection by Immunohistochemistry in Patients with Urothelial Bladder Carcinoma , 2007, Urologia Internationalis.

[27]  C. Vicentini,et al.  Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. , 2007, Oncology reports.

[28]  J. Trachtenberg,et al.  Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.

[29]  A. Carvalho,et al.  High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients , 2007, Clinical Cancer Research.

[30]  G. Cancel-Tassin,et al.  Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. , 2007, European urology.

[31]  M. Rubin,et al.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. , 2007, Urology.

[32]  I. Thompson,et al.  Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[33]  S. Halachmi,et al.  Molecular Detection of Bladder Cancer by Fluorescence Microsatellite Analysis and an Automated Genetic Analyzing System , 2007, TheScientificWorldJournal.

[34]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[35]  M. Knowles,et al.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer , 2007, The Journal of pathology.

[36]  S. Dhanasekaran,et al.  Integrative analysis of genomic aberrations associated with prostate cancer progression. , 2007, Cancer research.

[37]  George Tseng,et al.  Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. , 2007, Cancer research.

[38]  M. Knowles,et al.  Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer , 2007, Oncogene.

[39]  R. Knuechel,et al.  Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions , 2007, Journal of Clinical Pathology.

[40]  C. Cordon-Cardo,et al.  Prognostic significance of p27Kip1 expression in bladder cancer , 2007, BJU international.

[41]  Zhao Zhigang,et al.  Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer , 2007, The Prostate.

[42]  C. Marsit,et al.  Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. , 2007, Carcinogenesis.

[43]  D. Grignon,et al.  Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Xin-yang Wang,et al.  Primary application study in early diagnosis of bladder cancer by survivin molecular beacons. , 2007, Urology.

[45]  P. Tan,et al.  Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. , 2007, Urologic oncology.

[46]  J. Inazawa,et al.  Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells , 2007, Cancer science.

[47]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.

[48]  J. Inazawa,et al.  Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation , 2007, British Journal of Cancer.

[49]  M. Höglund.  Bladder cancer, a two phased disease? , 2007, Seminars in cancer biology.

[50]  Erin E. Carlson,et al.  Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q , 2007, Human Genetics.

[51]  Jian Gu,et al.  Matrix Metalloproteinase Polymorphisms Are Associated with Bladder Cancer Invasiveness , 2007, Clinical Cancer Research.

[52]  Klaus Jung,et al.  Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. , 2007, The Journal of urology.

[53]  J. Masters.  Clinical applications of expression profiling and proteomics in prostate cancer. , 2007, Anticancer research.

[54]  M. Rubin,et al.  Morphological features of TMPRSS2–ERG gene fusion prostate cancer , 2007, The Journal of pathology.

[55]  R. Datar,et al.  The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer. , 2007, Urologic oncology.

[56]  A. D. De Marzo,et al.  Abnormal DNA methylation, epigenetics, and prostate cancer. , 2007, Frontiers in bioscience : a journal and virtual library.

[57]  Yusuke Nakamura,et al.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.

[58]  J. Schalken,et al.  Molecular markers for prostate cancer. , 2007, Cancer letters.

[59]  L. Bubendorf,et al.  KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer , 2007, Oncogene.

[60]  S. Cross,et al.  Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer , 2007, Clinical Cancer Research.

[61]  Y. Lotan,et al.  Survivin expression is associated with bladder cancer presence, stage, progression, and mortality , 2007 .

[62]  Ishtiaq Rehman,et al.  Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage , 2007, Clinical Cancer Research.

[63]  G. Sauter,et al.  Molecular staging of prostate cancer in the year 2007 , 2007, World Journal of Urology.

[64]  P. Koivisto,et al.  Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. , 2007, Human Pathology.

[65]  H. Wang,et al.  Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells , 2007, Molecular Cancer Therapeutics.

[66]  R. Henrique,et al.  Epigenetic Markers for Molecular Detection of Prostate Cancer , 2007, Disease markers.

[67]  L. Kiemeney,et al.  Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. , 2007, European urology.

[68]  A. Chkhotua,et al.  Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades. , 2007, Georgian medical news.

[69]  Y. Lotan,et al.  Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. , 2007, The Journal of urology.

[70]  M. Dunn,et al.  Urinary markers for prostate cancer , 2007, BJU international.

[71]  C. Roehrborn,et al.  Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. , 2007, The Lancet. Oncology.

[72]  C. Cordon-Cardo,et al.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. , 2007, The Journal of clinical investigation.

[73]  K. D. Sørensen,et al.  Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array , 2007, British Journal of Cancer.

[74]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[75]  A. Evans,et al.  Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer. , 2007, Neoplasia.

[76]  M. Babjuk,et al.  Molecular cytogenetic characterization and diagnostics of bladder cancer. , 2007, Neoplasma.

[77]  R. Baffa,et al.  Chromosomal deletions in bladder cancer: shutting down pathways. , 2007, Frontiers in bioscience : a journal and virtual library.

[78]  F. Real,et al.  Molecular biology of bladder cancer , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[79]  F. Zaeri,et al.  Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. , 2007, Urology journal.

[80]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.

[81]  M. Becich,et al.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process , 2007, BMC Cancer.

[82]  Ram H Datar,et al.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Gazdar,et al.  Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. , 2006, Cancer letters.

[84]  W. Schulz,et al.  DNA methylation alterations in urothelial carcinoma , 2006, Cancer biology & therapy.

[85]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[86]  L. Brown,et al.  A phase II study utilizing oxaliplatin and docetaxel in androgen independent prostate cancer in men treated with up to two prior chemotherapy regimens. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  S. Pang,et al.  Proteomic comparison of prostate cancer cell lines LNCaP‐FGC and LNCaP‐r reveals heatshock protein 60 as a marker for prostate malignancy , 2006, The Prostate.

[88]  E. Gelmann,et al.  Molecular biology of prostate-cancer pathogenesis , 2006, Current opinion in urology.

[89]  S. Srinivas,et al.  Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. , 2006, Urology.

[90]  A. Chiocchetti,et al.  Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7 , 2006, The Prostate.

[91]  Sangeeta Bafna,et al.  Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas , 2006, The Prostate.

[92]  S. Cross,et al.  Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls , 2006, Oncogene.

[93]  R. Knuechel,et al.  Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. , 2006, Human pathology.

[94]  K. Kawamoto,et al.  p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. , 2006, Biochemical and biophysical research communications.

[95]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[96]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[97]  T. Schlott,et al.  Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. , 2006, International journal of molecular medicine.

[98]  G. Li,et al.  Mutant p53 melanoma cell lines respond differently to CP‐31398‐induced apoptosis , 2005, The British journal of dermatology.

[99]  M. Galsky.  The role of taxanes in the management of bladder cancer. , 2005, The oncologist.

[100]  Liang Cheng,et al.  Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis , 2005, Clinical Cancer Research.

[101]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[102]  A. Scorilas,et al.  Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[103]  Mitsutoshi Nakamura,et al.  High Expression of a New Marker PCA-1 in Human Prostate Carcinoma , 2005, Clinical Cancer Research.

[104]  Rainer Grobholz,et al.  Calcium-Binding Proteins S100A8 and S100A9 as Novel Diagnostic Markers in Human Prostate Cancer , 2005, Clinical Cancer Research.

[105]  S. Lerner.  Bladder cancer clinical trials. , 2005, Urologic oncology.

[106]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[107]  A. Bankfalvi,et al.  Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? , 2005, BJU international.

[108]  P. Laird,et al.  Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Ishtiaq Rehman,et al.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  V. Pankratz,et al.  Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. , 2005, The Journal of urology.

[111]  Rajvir Dahiya,et al.  Epigenetic changes in prostate cancer: implication for diagnosis and treatment. , 2005, Journal of the National Cancer Institute.

[112]  R. Knuechel,et al.  Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. , 2005, European urology.

[113]  A. Barberis,et al.  CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity , 2004, Journal of Negative Results in Biomedicine.

[114]  Gangning Liang,et al.  Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients , 2004, Clinical Cancer Research.

[115]  M. Demma,et al.  CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73* , 2004, Journal of Biological Chemistry.

[116]  W. Gerald,et al.  Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control , 2004, Nature.

[117]  R. Millikan,et al.  Focus on bladder cancer. , 2004, Cancer cell.

[118]  D. Neal,et al.  Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer , 2004, Clinical Cancer Research.

[119]  Jane Fridlyand,et al.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors , 2004 .

[120]  Avri Ben-Ze'ev,et al.  Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway , 2004, Oncogene.

[121]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[122]  J. Lunec,et al.  Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2 , 2004, British Journal of Cancer.

[123]  K. Bloom,et al.  HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. , 2004, Urology.

[124]  S. Groshen,et al.  Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  S. Shariat,et al.  p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  R. Uzzo,et al.  Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel , 2004, Clinical Cancer Research.

[127]  T. H. van der Kwast,et al.  FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma , 2004, Cancer Research.

[128]  S. Galiègue,et al.  SR31747A: a peripheral &sgr; ligand with potent antitumor activities , 2004, Anti-cancer drugs.

[129]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[130]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[131]  S. Catz,et al.  BCL-2 in prostate cancer: A minireview , 2004, Apoptosis.

[132]  Y. Ding-wei,et al.  Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors , 2004, Urological Research.

[133]  M. Goepel,et al.  E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma , 2004, Urological Research.

[134]  P. Athanassiadou,et al.  Telomerase expression as a marker in prostate cancer: correlation to clinicopathologic predictors. , 2003, Journal of experimental & clinical cancer research : CR.

[135]  H. Wallerand,et al.  FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. , 2003, Cancer research.

[136]  M. Knowles,et al.  Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. , 2003, Cancer research.

[137]  R. Paterson,et al.  Molecular genetic alterations in the laser‐capture–microdissected stroma adjacent to bladder carcinoma , 2003, Cancer.

[138]  C. Dinney,et al.  Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. , 2003, Urologic oncology.

[139]  Xin Ma,et al.  Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. , 2003, The Journal of urology.

[140]  A. Gotoh,et al.  Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type-p53 but not in p53-mutated bladder cancer cells , 2003, Urological Research.

[141]  K. Rieger-Christ,et al.  Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection , 2003, Cancer.

[142]  Wen-Jeng Wu,et al.  Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. , 2003, The Journal of urology.

[143]  P. Febbo,et al.  Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.

[144]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  K. Shiraishi,et al.  P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder. , 2003, Anticancer research.

[146]  C. Dinney,et al.  Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  J. Jones,et al.  Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. , 2003, The Journal of urology.

[148]  A. Chan,et al.  Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients , 2003, International journal of cancer.

[149]  M. Parmar,et al.  Can p53 staining be used to identify patients with aggressive superficial bladder cancer? , 2003, Journal of Pathology.

[150]  Wei Ye,et al.  Inhibition of DNA methylation and reactivation of silenced genes by zebularine. , 2003, Journal of the National Cancer Institute.

[151]  W. Schulz,et al.  Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. , 2003, European urology.

[152]  D. Johnston,et al.  Genetic markers useful for distinguishing between organ‐confined and locally advanced prostate cancer , 2003, Genes, chromosomes & cancer.

[153]  J. Shay,et al.  Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. , 2003, Cancer research.

[154]  R. Knuechel,et al.  Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses , 2003, The Journal of pathology.

[155]  J. Adolfsson,et al.  Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[156]  K. Iczkowski,et al.  Telomerase reverse transcriptase subunit immunoreactivity , 2002, Cancer.

[157]  A. Feller,et al.  HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications , 2002, International journal of cancer.

[158]  N. Socci,et al.  Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. , 2002, Cancer research.

[159]  P. Schellhammer,et al.  Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. , 2002, The Journal of urology.

[160]  M. Vihinen,et al.  Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer , 2002, Laboratory Investigation.

[161]  A. Sandberg.  Cytogenetics and molecular genetics of bladder cancer: a personal view. , 2002, American journal of medical genetics.

[162]  G. Pfeifer,et al.  Frequent hypermethylation of the RASSF1A gene in prostate cancer , 2002, Oncogene.

[163]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[164]  P. Carroll,et al.  CpG hypermethylation of promoter region and inactivation of E‐cadherin gene in human bladder cancer , 2002, Molecular carcinogenesis.

[165]  H. Frierson,et al.  Defining the region(s) of deletion at 6q16–q22 in human prostate cancer , 2002, Genes, chromosomes & cancer.

[166]  A. Protopopov,et al.  The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. , 2002, Cancer research.

[167]  Gang Li,et al.  The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. , 2002, Experimental cell research.

[168]  Matthias Kretzler,et al.  Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. , 2002, The American journal of pathology.

[169]  Angie Rizzino,et al.  Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. , 2002, Carcinogenesis.

[170]  A. Harris,et al.  Angiogenesis in bladder cancer--prognostic marker and target for future therapy. , 2002, Surgical oncology.

[171]  R. Cardiff,et al.  Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. , 2002, Cancer research.

[172]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[173]  J. Cheville,et al.  A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. , 2002, The Journal of urology.

[174]  K. Wester,et al.  Human urinary bladder carcinomas express adenovirus attachment and internalization receptors , 2002, Gene Therapy.

[175]  H. Moch,et al.  Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer , 2002, Oncogene.

[176]  T. Mattfeldt,et al.  Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization. , 2002, European urology.

[177]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[178]  Y. Shang,et al.  Formation of the androgen receptor transcription complex. , 2002, Molecular cell.

[179]  Peter A. Humphrey,et al.  Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.

[180]  M. Gleave,et al.  Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy , 2002, The Prostate.

[181]  M. Schuler,et al.  Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  D. Bostwick,et al.  Loss of p53 and c-myc Overrepresentation in Stage T2-3N1-3M0 Prostate Cancer are Potential Markers for Cancer Progression , 2002, Modern Pathology.

[183]  C. Cordon-Cardo,et al.  Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[184]  S. Friedman,et al.  KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer , 2001, Science.

[185]  K. Rieger-Christ,et al.  Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions. , 2001, The Journal of urology.

[186]  B. Dave,et al.  Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[187]  G. Adessi,et al.  Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. , 2001, The Journal of urology.

[188]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. , 2001, Cancer research.

[189]  A. Shabsigh,et al.  Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells * , 2001, The Prostate.

[190]  C. Dinney,et al.  Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[191]  C. Cordon-Cardo,et al.  HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[192]  A. Weeraratna,et al.  Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[193]  M. Wirth,et al.  LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13. , 2001, Anticancer research.

[194]  L. Bubendorf,et al.  Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. , 2001, American journal of clinical pathology.

[195]  C. Abbou,et al.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[196]  J. Trachtenberg,et al.  HPC2 variants and screen-detected prostate cancer. , 2001, American journal of human genetics.

[197]  D. Ornstein,et al.  Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. , 2001, The Journal of urology.

[198]  Nobuyuki Itoh,et al.  Fibroblast growth factors , 2001, Genome Biology.

[199]  R. Beltz,et al.  Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. , 2001, Urologic oncology.

[200]  T. H. van der Kwast,et al.  The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.

[201]  H. Kanayama.  Matrix metalloproteinases and bladder cancer. , 2001, The journal of medical investigation : JMI.

[202]  H. Grossman,et al.  Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. , 2001, Oncology reports.

[203]  T. Wheeler,et al.  E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. , 2001, Urology.

[204]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[205]  W. Isaacs,et al.  Detection and analysis of β‐catenin mutations in prostate cancer , 2000 .

[206]  C. Dinney,et al.  Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[207]  J. Epstein,et al.  Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer , 2000 .

[208]  O. Kallioniemi,et al.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. , 2000, Cancer research.

[209]  C. Wood,et al.  Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[210]  K. Miller,et al.  Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. , 2000, Cancer research.

[211]  B. Eussen,et al.  Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. , 2000, Journal of the National Cancer Institute.

[212]  R. Forough,et al.  Overexpression of a secretory form of FGF‐1 promotes MMP‐1‐mediated endothelial cell migration , 2000, Journal of cellular biochemistry.

[213]  J. Trachtenberg,et al.  Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. , 2000, The Journal of urology.

[214]  J. Favaloro,et al.  Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. , 2000, Journal of molecular endocrinology.

[215]  Y. Shyr,et al.  Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. , 2000, The American journal of pathology.

[216]  C. Abbou,et al.  Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information , 2000, British Journal of Cancer.

[217]  H. Tanke,et al.  Identification of Genetic Markers for Prostatic Cancer Progression , 2000, Laboratory Investigation.

[218]  M. Rubin,et al.  10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. , 2000, Human pathology.

[219]  M. Augustus,et al.  Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. , 2000, The Journal of urology.

[220]  Pier Paolo Pandolfi,et al.  The Multiple Roles of PTEN in Tumor Suppression , 2000, Cell.

[221]  X. Castellsagué,et al.  Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. , 2000, European journal of cancer.

[222]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[223]  L. Pagliaro.  Gene therapy for bladder cancer , 2000, World Journal of Urology.

[224]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[225]  J. Schleutker,et al.  Androgen receptor gene mutations in hormone‐refractory prostate cancer , 1999, The Journal of pathology.

[226]  W. Stadler,et al.  Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. , 1999, Cancer research.

[227]  T. H. van der Kwast,et al.  Decreased expression of cd44 in metastatic prostate cancer , 1999, International journal of cancer.

[228]  D. Bostwick,et al.  Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.

[229]  H. Moch,et al.  Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). , 1999, Cancer research.

[230]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[231]  T. Bouras,et al.  Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade , 1999, The Journal of pathology.

[232]  M. T. Abreu-Martin,et al.  Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.

[233]  M. Newton,et al.  p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. , 1999, Cancer research.

[234]  H. Frierson,et al.  Three distinct regions of allelic loss at 13q14, 13q21‐22, and 13q33 in prostate cancer , 1999, Genes, chromosomes & cancer.

[235]  D. Bostwick,et al.  Genetic and Chromosomal Alterations in Prostatic Intraepithelial Neoplasia and Carcinoma Detected by Fluorescence in situ Hybridization , 1999, European Urology.

[236]  M. Becich,et al.  Methylation of the CD44 metastasis suppressor gene in human prostate cancer. , 1999, Cancer research.

[237]  J. Isaacs,et al.  Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). , 1999, Cancer research.

[238]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[239]  W. Figg,et al.  The androgen receptor: genetic considerations in the development and treatment of prostate cancer , 1999, Journal of Molecular Medicine.

[240]  A Hofstetter,et al.  Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. , 1999, The American journal of pathology.

[241]  Y. Bignon,et al.  p16 involvement in primary bladder tumors: analysis of deletions and mutations. , 1999, International journal of oncology.

[242]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[243]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[244]  C. Dinney,et al.  Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[245]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[246]  R. Cote,et al.  Molecular determinants of outcome in bladder cancer. , 1999, The cancer journal from Scientific American.

[247]  A. Kibel,et al.  Identification of 12p as a region of frequent deletion in advanced prostate cancer. , 1998, Cancer research.

[248]  A. Deitch,et al.  Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors , 1998, Cancer.

[249]  T. Mashimo,et al.  Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. , 1998, Cancer research.

[250]  Pär Stattin,et al.  Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer , 1998 .

[251]  L. Hudson,et al.  Epidermal growth factor (EGF)‐ and scatter factor/hepatocyte growth factor (SF/HGF)‐mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)‐9 , 1998, Journal of cellular physiology.

[252]  J. Isaacs,et al.  Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. , 1998, Cancer research.

[253]  N. Neff,et al.  Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[254]  S. Groshen,et al.  Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. , 1998, Journal of the National Cancer Institute.

[255]  T. Visakorpi,et al.  Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.

[256]  Chunde Li,et al.  Chromosome 16q24 deletion and decreased E‐cadherin expression: Possible association with metastatic potential in prostate cancer , 1998, The Prostate.

[257]  R. DePinho,et al.  Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth , 1998, Nature.

[258]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[259]  P. Jones,et al.  The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. , 1998, Cancer research.

[260]  S. Campbell,et al.  Molecular mediators of angiogenesis in bladder cancer. , 1998, Cancer research.

[261]  A. Mes-Masson,et al.  Analysis of the p16 tumor suppressor gene in early‐stage prostate cancer , 1998, Molecular carcinogenesis.

[262]  C. Larsson,et al.  Identification of two distinct deleted regions on chromosome 13 in prostate cancer , 1998, Oncogene.

[263]  J. Nelson,et al.  Prostate cancer metastasis-suppressor genes: a current perspective. , 1998, In vivo.

[264]  T. Ørntoft,et al.  Molecular alterations in bladder cancer , 1998, Urological Research.

[265]  A. Harris,et al.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. , 1997, Cancer research.

[266]  R. deVere White,et al.  Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[267]  J. Piette,et al.  Mdm2: keeping p53 under control , 1997, Oncogene.

[268]  A. Nagafuchi,et al.  Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. , 1997, Cancer research.

[269]  G. Bubley,et al.  Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[270]  R. T. Curtis,et al.  A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. , 1997, Genomics.

[271]  T. H. van der Kwast,et al.  The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[272]  O. Cussenot,et al.  Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. , 1997, Cancer research.

[273]  J. Isaacs,et al.  CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. , 1997, Cancer research.

[274]  S. Groshen,et al.  Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.

[275]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[276]  D. Grignon,et al.  p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. , 1997, Journal of the National Cancer Institute.

[277]  Peter A. Jones,et al.  p53 and treatment of bladder cancer , 1997, Nature.

[278]  M. Loda,et al.  Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[279]  P. Korkolopoulou,et al.  The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. , 1997, Pathology, research and practice.

[280]  T. P. Pretlow,et al.  Altered expression of CD44 in human prostate cancer during progression. , 1996, American journal of clinical pathology.

[281]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[282]  K. Akakura,et al.  Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancer: Relation to Antiandrogen Withdrawal Syndrome , 1996, The Prostate.

[283]  K. Miyazono,et al.  Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[284]  J. Seigne,et al.  Characteristics of invasive bladder cancers: histological and molecular markers. , 1996, Seminars in urologic oncology.

[285]  J. Isaacs,et al.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.

[286]  R. deVere White,et al.  Alterations of the retinoblastoma gene in human prostate adenocarcinoma , 1996, Genes, chromosomes & cancer.

[287]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[288]  D. Bostwick,et al.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.

[289]  J. Weissenbach,et al.  Loss of the chromosomal region 10q23-25 in prostate cancer. , 1995, Cancer research.

[290]  G. Hannon,et al.  Deletion of the p16 and p15 genes in human bladder tumors. , 1995, Journal of the National Cancer Institute.

[291]  R. Beart,et al.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. , 1995, Cancer research.

[292]  F. Waldman,et al.  Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. , 1995, Human pathology.

[293]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[294]  J. Barrett,et al.  KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. , 1995, Science.

[295]  P. Lipponen.  Expression of c‐myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer , 1995, The Journal of pathology.

[296]  J. Patard,et al.  Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. , 1995, British Journal of Cancer.

[297]  K. Friedrichs,et al.  Are CD44 variant isoforms involved in human tumour progression? , 1995, Cancer surveys.

[298]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[299]  W. Grizzle,et al.  Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas , 1994, The Prostate.

[300]  W. Benedict,et al.  Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[301]  W. Isaacs,et al.  Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. , 1994, Cancer research.

[302]  P. Lipponen,et al.  Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. , 1994, British Journal of Cancer.

[303]  R. Hruban,et al.  Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. , 1994, The New England journal of medicine.

[304]  E. Gelmann,et al.  p53 oncogene mutations in human prostate cancer specimens. , 1994, The Journal of urology.

[305]  J. Figge,et al.  Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. , 1994, Human pathology.

[306]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[307]  W. W. Nichols,et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.

[308]  C. Cordon-Cardo,et al.  Genetic alterations in bladder cancer , 1993, The Lancet.

[309]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[310]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[311]  E. Liu,et al.  p53 gene alterations in human prostate carcinoma. , 1993, The Journal of urology.

[312]  M. Knowles,et al.  Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. , 1993, Oncogene.

[313]  M. Williamson,et al.  Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. , 1993, Cancer research.

[314]  Steinberg Gd,et al.  Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. , 1992 .

[315]  B. Czerniak,et al.  Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. , 1992, Human pathology.

[316]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[317]  E. Messing.  Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. , 1992, Seminars in surgical oncology.

[318]  A. Sahin,et al.  Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. , 1992, Journal of the National Cancer Institute.

[319]  L. Koss.  Bladder caner from a perspective of 40 years , 1992, Journal of cellular biochemistry. Supplement.

[320]  Joseph R. Nevins,et al.  The E2F transcription factor is a cellular target for the RB protein , 1991, Cell.

[321]  W. Lee,et al.  Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[322]  N. Kyprianou,et al.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. , 1990, Cancer research.

[323]  J D Siegal,et al.  Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancers , 1988, The Prostate.

[324]  L. Orci,et al.  Basic fibroblast growth factor induces angiogenesis in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.